Related Experiment Video
Updated: Feb 1, 2026

Cerenkov Luminescence Imaging CLI for Cancer Therapy Monitoring
Published on: November 13, 2012
First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction
Samantha M Vogel1, Leticia V Smith2, Evan J Peterson3
1Seton Healthcare Family, Dell Seton Medical Center at the University of Texas at Austin, Austin, TX, USA.
Objective:
To review evidence behind anticoagulants in cancer-associated venous thromboembolism (VTE) with a focus on low-molecular-weight heparins (LMWH) and the role of direct oral anticoagulants (DOACs).
Data Sources:
PubMed was searched using terms "venous thromboembolism," "cancer," and "anticoagulation." This search was restricted to clinical trials, meta-analyses, and subgroup analyses. Additional references were identified from reviewing literature citations.
Study Selection:
English-language prospective and retrospective studies assessing the efficacy and safety of LMWH and DOACs in patients with cancer.
Data Analysis:
Several trials were analyzed that compared anticoagulation therapies for prevention of recurrent VTE in patients with cancer. Many studies comparing LMWH and vitamin K antagonists (VKAs) found nonsignificant differences between therapies. A single study demonstrated that LMWHs are superior to VKAs. This evidence supporting LMWH for long-term VTE treatment in patients with cancer is based on comparison to VKA, but results are limited by methodological issues, and the benefit of LMWH may be driven by poor control. Subanalyses of DOAC trials suggest these are equally or more effective as VKA in cancer, but this conclusion is underpowered.
Conclusion:
DOACs have the potential to bypass many challenges with traditional therapy. After analyzing the evidence available, we conclude that after careful consideration of risks and benefits, use of DOACs for VTE treatment are a reasonable option in patients with cancer.
More Related Videos
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Secondary Active Transport
Secondary Healthcare System
Gene Therapy